Harbour BioMed to present phase II data of HBM4003 & tislelizumab combination in MSS metastatic colorectal cancer at ESMO 2025: Cambridge, Massachusetts Friday, August 1, 2025, 18 ...

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, July 29, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical comp ...

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, July 30, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel ...

Q2 2025 Earnings Call Transcript August 12, 2025 Acumen Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.68 EPS, expectations were $-0.54. Operator: Good day, and welcome to ...

August 05, 2025 - The growing prevalence of chronic illnesses is a major factor driving revenue growth in the bispecific ...

From new payload linkers to artificial intelligence partnerships, advances in ADC pipelines push forward selective cancer therapies that minimize side effects.

ZUG, Switzerland, August 5, 2025 – MoonLake Immunotherapeutics (NASDAQ:MLTX) (“MoonLake” or the “Company”), a clinical-stage biotechnology company focused on creating next-level therapies for ...

Sanofi’s shift to immunology, AI-driven R&D, and strong pipeline offset risks from patent cliffs and legal issues. See why ...

For outsourcing and manufacturing professionals, 2024 may be remembered as the year capacity and partnerships took center ...

Christopher Cano has been picked as the new Chief Executive Officer of Cellergy Pharma Inc., a preclinical biotechnology firm ...